DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD
DASH.HARVARD.EDU

HARVARD LIBRARY
Office for Scholarly Communication

Dysregulation of Host Cellular microRNA Expression by the Human Papillomavirus E6 and E7 Oncoproteins

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:40046534

Terms of Use
This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. Submit a story .

Accessibility

43	miR-221	hsa-miR-221-3p	agcuacauugucugcuggguuuc	YES	hepatocellular carcinoma, prostate cancer, NSCLC, ovarian cancer, gastric cancer	PMID: 24124720, PMID: 24583788, PMID: 22009180, PMID: 23569131, PMID: 22432036
44	miR-222	hsa-miR-222-3p	agcuacaucuggcuacugggu	YES	acute lymphoblastic leukemia, ESCC (x2), hepatocellular carcinoma (x2), NSCLC (x3), gastric cancer, breast cancer	PMID: 23484694, PMID: 24651474, PMID: 22105822, PMID: 23342174, PMID: 22860003, PMID: 24390317, PMID: 24531034, PMID: 24595450, PMID: 24440980, PMID: 22009180
45	miR-223	hsa-miR-223-3p	ugucaguuugucaaauacccca	YES	pancreatic cancer, breast cancer, ovarian cancer	PMID: 24578785, PMID: 24498016, PMID: 24366298
46	miR-25	hsa-miR-25-3p	cauugcacuugucucggucuga	YES	ESCC (x2), gastric cancer	PMID: 24651474, PMID: 24595006, PMID: 24390317
47	miR-26a	hsa-miR-26a-5p	uucaaguaauccaggauaggcu	YES	hepatocellular carcinoma, ovarian cancer (x2)	PMID: 22105822, PMID: 24466274, PMID: 23542579
48	miR-27a	hsa-miR-27a-3p	uucacaguggcuaaguuccgc	YES	NSCLC, hepatocellular carcinoma, gastric cancer	PMID: 21544802, PMID: 22105822, PMID: 21112772
49	miR-29a	hsa-miR-29a-3p	uagcaccaucugaaaucgguua	YES	colorectal cancer (x5), breast cancer, ovarian cancer	PMID: 19876917, PMID: 19201770, PMID: 24498016, PMID: 23673725, PMID: 23625654, PMID: 18954897, PMID: 23267864
50	miR-29b	hsa-miR-29b-3p	uagcaccauuugaaaucaguguu	YES	potential normalizer	
51	miR-29c	hsa-miR-29c-3p	uagcaccauuugaaaucgguua	YES	NSCLC (x2), mesothelioma, colorectal cancer	PMID: 21544802, PMID: 22617246, PMID: 24523873, PMID: 23970420
52	miR-320a	hsa-miR-320a	aaaagcuggguugagagggcga	YES	colon cancer	PMID: 24400111
53	miR-335	hsa-miR-335-5p	ucaagagcaauaacgaaaaaugu	YES	breast cancer, colorectal cancer	PMID: 20801493, PMID: 23267864
54	miR-34a	hsa-miR-34a-5p	uggcagugucuuagcugguugu	YES	multiple myeloma, DLBCL, breast cancer, colorectal cancer, gastric cancer	PMID: 21987025, PMID: 24241494, PMID: 23748853, PMID: 22648208, PMID: 21112772
55	miR-34b	hsa-miR-34b-3p	caaucacuaacuccacugccau	NO	osteosarcoma	PMID: 24063968
56	miR-375	hsa-miR-375	uuuguucguucggcucgcguga	YES	prostate cancer, ESCC (x2), pancreatic cancer (x2), NSCLC (x2), breast cancer	PMID: 22240788, PMID: 22519435, PMID: 23329235, PMID: 24390317, PMID: 24048453, PMID: 24404590, PMID: 24513341, PMID: 22952344
57	miR-376c	hsa-miR-376c-3p	aacauagaggaaauuccacgu	NO	breast cancer (x2), gastric cancer	PMID: 24194846, PMID: 22927033, PMID: 22432036
58	miR-378	hsa-miR-378a-3p	acuggacuuggagucagaaggc	NO	colorectal cancer, gastric cancer	PMID: 24423916, PMID: 22432036
59	miR-409	hsa-miR-409-3p	gaauguugcucggugaaccccu	YES	breast cancer (x2)	PMID: 24194846, PMID: 22927033
60	miR-451	hsa-miR-451a	aaaccguuaccauuacugaguu	YES	potential hemolysis marker, colon cancer, breast cancer, gastric cancer (x2)	PMID: 24400111, PMID: 23301032, PMID: 24595006, PMID: 22262318
61	miR-483-5p	hsa-miR-483-5p	aagacgggaggaaagaagggag	NO	ESCC, breast cancer, ovarian cancer	PMID: 24651474, PMID: 21060830, PMID: 24223734
62	miR-486	hsa-miR-486-5p	uccuguacugagcugccccgag	YES	potential hemolysis marker, NSCLC, gastric cancer (x2), lung cancer, breast cancer	PMID: 21116241, PMID: 24595006, PMID: 21864403, PMID: 22262318, PMID: 24498016
63	miR-574	hsa-miR-574-3p	cacgcucaugcacacacccaca	YES	prostate cancer, NSCLC, breat cancer	PMID: 22240788, PMID: 21258252, PMID: 21060830
64	miR-625-3p	hsa-miR-625-3p	gacuauagaacuuucccccuca	NO	mesothelioma, lung cancer	PMID: 22617246, PMID: 22675530
65	miR-652	hsa-miR-652-3p	aauggcgccacuaggguugug	YES	breast cancer (x2), colorectal cancer	PMID: 24194846, PMID: 24498016, PMID: 24022433
66	miR-9	hsa-miR-9-5p	ucuuugguuaucuagcuguauga	YES	endometrial carcinoma	PMID: 22987275
67	miR-92a	hsa-miR-92a-3p	uauugcacuugucccggccugu	NO	non-Hodgkin lymphoma, leukemia (x2), gastric cancer, colorectal cancer (x4), mesothelioma, endometrial carcinoma, ovarian cancer (x3)	PMID: 21383985, PMID: 19440243, PMID: 21182798, PMID: 24595006, PMID: 19876917, PMID: 22617246, PMID: 22987275, PMID: 22648208, PMID: 23673725, PMID: 23625654, PMID: 18954897, PMID: 23963852, PMID: 24366298

68	miR-93-5p	hsa-mir-93-5p	caaagugcuguucgugcagguag	YES	acute myeloid leukemia, NSCLC, breast cancer (x2), ovarian cancer	PMID: 23437222, PMID: 24523873, PMID: 24498016, PMID: 23748853, PMID: 18954897
69	x-control	x-control	x-control	N/A	internal reference	
70	blank	blank	none	N/A	internal reference	

References

PMID:

18318758 Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br J Haematol.* 2008;141(5):672-675.

18348159 Wang M, Tan LP, Dijkstra MK, et al. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. *J Pathol.* 2008;215(1):13-20.

18954897 Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. *Gynecol Oncol.* 2009;112(1):55-59.

19201770 Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. *Gut.* 2009;58(10):1375-1381.

19440243 Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. *PLoS One.* 2009;4(5):e5532.

19723895 Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. *Cancer Prev Res (Phila).* 2009;2(9):807-813.

19876917 Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *Int J Cancer.* 2010;127(1):118-126.

20234369 Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. *Br J Cancer.* 2010;102(7):1174-1179.

20801493 Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. *Gynecol Oncol.* 2010;119(3):586-593.

21060830 Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. *PLoS One.* 2010;5(10):e13735.

21112772 Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. *Eur J Cancer.* 2011;47(5):784-791.

21116241 Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. *Lab Invest.* 2011;91(4):579-587.

21139804 Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. *Am J Transl Res.* 2010;3(1):28-47.

21182798 Ohyashiki JH, Umezu T, Kobayashi C, et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. *BMC Res Notes.* 2010;3:347.

21206010 Guo HQ, Huang GL, Guo CC, Pu XX, Lin TY. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. *Dis Markers.* 2010;29(5):251-258.

21258252 Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. *J Thorac Oncol.* 2011;6(3):482-488.

21278583 Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. *J Clin Gastroenterol.* 2011;45(4):355-360.

21383985 Ohyashiki K, Umezu T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. *PLoS One.* 2011;6(2):e16408.

21398193 Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. *Mol Oncol.* 2011;5(3):281-291.

21445232 Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLoS One.* 2011;6(3):e17745.

21544802 Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. *Int J Cancer.* 2012;130(6):1378-1386.

21602271 Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. *Ann Rheum Dis.* 2011;70(8):1496-1506.

21627863 Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. *Chin J Cancer.* 2011;30(6):407-414.

21721011 Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. *J Surg Oncol.* 2011;104(7):847-851.

21749846 Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. *J Hepatol.* 2012;56(1):167-175.

21864403 Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. *BMC Cancer.* 2011;11:374.

21904633 Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. *Int J Clin Exp Pathol.* 2011;4(6):575-586.

21920043 Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. *BMC Cancer.* 2011;11:393.

21987025 Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. *Ann Hematol.* 2012;91(4):553-559.

22009180 Lin Q, Mao W, Shu Y, et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. *J Cancer Res Clin Oncol.* 2012;138(1):85-93.

22045190 Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. *Br J Cancer.* 2011;105(11):1733-1740.

22105822 Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. *J Clin Oncol.* 2011;29(36):4781-4788.

22156446 Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. *Onkologie.* 2011;34(12):675-680.

22240788 Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. *Br J Cancer.* 2012;106(4):768-774.

22262318 Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. *Br J Cancer.* 2012;106(4):740-747.

22298119 Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. *Prostate.* 2012;72(13):1469-1477.

22389695 Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. *PLoS One.* 2012;7(2):e32307.

22406928 Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. *Mol Med Rep.* 2012;5(6):1514-1520.

22432036 Song MY, Pan KF, Su HJ, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. *PLoS One.* 2012;7(3):e33608.

22519435 Komatsu S, Ichikawa D, Takeshita H, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. *Expert Opin Biol Ther.* 2012;12 Suppl 1:S53-59.

22541087 Ge TT, Liang Y, Fu R, et al. [Expressions of miR-21, miR-155 and miR-210 in plasma of patients with lymphoma and its clinical significance]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.* 2012;20(2):305-309.

22617246 Kirschner MB, Cheng YY, Badrian B, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. *J Thorac Oncol.* 2012;7(7):1184-1191.

22638884 Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. *J Cancer Res Clin Oncol.* 2012;138(10):1659-1666.

22648208 Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. *J Surg Oncol.* 2012;106(8):947-952.

22675530 Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. *PLoS One.* 2012;7(6):e38248.

22692639 Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. *Int J Mol Med.* 2012;30(3):680-686.

22806310 Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. *J Cancer Res Clin Oncol.* 2012;138(12):2045-2050.

22860003 Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. *PLoS One.* 2012;7(7):e41629.

22868372 Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. *Ann Surg.* 2012;256(3):544-551.

22891887 Liu R, Liao J, Yang M, et al. Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. *J Toxicol Environ Health A.* 2012;75(18):1154-1162.

22927033 Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. *Int J Cancer.* 2013;132(7):1602-1612.

22952344 Madhavan D, Zucknick M, Wallwiener M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. *Clin Cancer Res.* 2012;18(21):5972-5982.

22954417 Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. *J Transl Med.* 2012;10:186.

22956063 Li C, Li JF, Cai Q, et al. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. *Ann Surg Oncol.* 2013;20 Suppl 3:S397-405.

22983388 Cui EH, Li HJ, Hua F, et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. *Acta Pharmacol Sin.* 2013;34(2):309-313.

22987275 Torres A, Torres K, Pesci A, et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. *Int J Cancer.* 2013;132(7):1633-1645.

23212612 Gorur A, Balci Fidanci S, Dogruer Unal N, et al. Determination of plasma microRNA for early detection of gastric cancer. *Mol Biol Rep.* 2013;40(3):2091-2096.

23263848 Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in lung cancer. *Med Oncol.* 2013;30(1):353.

23267156 Komatsu S, Ichikawa D, Tsujiura M, et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. *Anticancer Res.* 2013;33(1):271-276.

23267864 Giráldez MD, Lozano JJ, Ramírez G, et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. *Clin Gastroenterol Hepatol.* 2013;11(6):681-688.e683.

23269581 Ouyang L, Liu P, Yang S, Ye S, Xu W, Liu X. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. *Med Oncol.* 2013;30(1):340.

23301032 Ng EK, Li R, Shin VY, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. *PLoS One.* 2013;8(1):e53141.

23307259 Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. *Med Oncol.* 2013;30(1):452.

23329235 Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. *Br J Cancer.* 2013;108(2):361-369.

23342174 Sanfiorenzo C, Ilie MI, Belaid A, et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. *PLoS One.* 2013;8(1):e54596.

23372341 Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. *Chin J Cancer Res.* 2013;25(1):46-54.

23377530 Zhang HL, Qin XJ, Cao DL, et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. *Asian J Androl.* 2013;15(2):231-235.

23391324 Fayyad-Kazan H, Bitar N, Najar M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. *J Transl Med.* 2013;11:31.

23437222 Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. *PLoS One.* 2013;8(2):e56718.

23484694 Lu XJ, Jiang Q, Huang PL, et al. [Preliminary analysis of aberrant expression of plasma miR-223 in pediatric acute lymphoblastic leukemia with a direct RT-PCR assay]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.* 2013;21(1):68-72.

23542579 Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. *Int J Gynecol Cancer.* 2013;23(4):673-679.

23569131 Hong F, Li Y, Xu Y, Zhu L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. *J Int Med Res.* 2013;41(1):64-71.

23579215 Hirajima S, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. *Br J Cancer.* 2013;108(9):1822-1829.

23625654 Liu GH, Zhou ZG, Chen R, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. *Tumour Biol.* 2013;34(4):2175-2181.

23673725 Brunet Vega A, Pericay C, Moya I, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. *Oncol Rep.* 2013;30(1):320-326.

23733518 Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. *J Surg Oncol.* 2013;108(2):89-92.

23748853 Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. *Clin Chem.* 2013;59(10):1489-1496.

23756108 Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. *Lung Cancer.* 2013;81(3):388-396.

23774211 Wang Y, Gu J, Roth JA, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. *Cancer Res.* 2013;73(15):4801-4809.

23797906 Chan M, Liaw CS, Ji SM, et al. Identification of circulating microRNA signatures for breast cancer detection. *Clin Cancer Res.* 2013;19(16):4477-4487.

23821659 Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood.* 2013;122(11):1891-1899.

23898484 Kumar S, Keerthana R, Pazhanimuthu A, Perumal P. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. *Indian J Biochem Biophys.* 2013;50(3):210-214.

23916610 Zhao J, Lei T, Xu C, et al. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. *Biochem Biophys Res Commun.* 2013;438(2):439-444.

23963852 Guo F, Tian J, Lin Y, Jin Y, Wang L, Cui M. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. *J Int Med Res.* 2013;41(5):1456-1461.

23970420 Menéndez P, Padilla D, Villarejo P, et al. Prognostic implications of serum microRNA-21 in colorectal cancer. *J Surg Oncol.* 2013;108(6):369-373.

24022433 Kanaan Z, Roberts H, Eichenberger MR, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. *Ann Surg.* 2013;258(3):400-408.

24048453 Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OB, Heegaard NH. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls. *Pancreas.* 2013;42(7):1107-1113.

24063968 Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating miR-34b in osteosarcoma. *Eur J Surg Oncol.* 2014;40(1):67-72.

24124720 Zhan MX, Li Y, Hu BS, et al. [Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance]. *Zhonghua Yi Xue Za Zhi.* 2013;93(23):1830-1832.

24157791 Wu H, Xiao Z, Wang K, Liu W, Hao Q. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. *Biochem Biophys Res Commun.* 2013;441(4):693-700.

24161319 Roncarati R, Viviani Anselmi C, Losi MA, et al. Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic Cardiomyopathy. *J Am Coll Cardiol.* 2014;63(9):920-927.

24194846 Cuk K, Zucknick M, Madhavan D, et al. Plasma microRNA panel for minimally invasive detection of breast cancer. *PLoS One.* 2013;8(10):e76729.

24212760 Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. *Int J Oncol.* 2014;44(1):53-58.

24222179 Jones K, Nourse JP, Keane C, Bhatnagar A, Gandhi MK. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. *Clin Cancer Res.* 2014;20(1):253-264.

24223734 Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. *PLoS One.* 2013;8(11):e77853.

24241494 Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. *Haematologica.* 2014;99(3):511-518.

24260062 Wang PY, Gong HT, Li BF, et al. Higher expression of circulating miR-182 as a novel biomarker for breast cancer. *Oncol Lett.* 2013;6(6):1681-1686.

24282590 Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. *PLoS One.* 2013;8(11):e81408.

24304648 Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. *Anticancer Drugs.* 2014;25(3):346-352.

24310813 Chen J, Wang W, Zhang Y, Chen Y, Hu T. Predicting distant metastasis and chemoresistance using plasma miRNAs. *Med Oncol.* 2014;31(1):799.

24366298 Shapira I, Oswald M, Lovecchio J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. *Br J Cancer.* 2014;110(4):976-983.

24390317 Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. *Mol Biol Rep.* 2014;41(3):1257-1266.

24400111 Shivapurkar N, Weiner LM, Marshall JL, et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. *PLoS One.* 2014;9(1):e84686.

24400911 Chen W, Wang H, Chen H, et al. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population. *Eur J Haematol.* 2014.

24404590 Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. *Gene.* 2014;534(1):60-65.

24416156 Anfossi S, Giordano A, Gao H, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. *PLoS One.* 2014;9(1):e83113.

24423916 Zanutto S, Pizzamiglio S, Ghilotti M, et al. Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. *Br J Cancer.* 2014;110(4):1001-1007.

24440980 Lv M, Zhu X, Chen W, Zhao J, Tang J. Searching for candidate microRNA biomarkers in detection of breast cancer: a meta-analysis. *Cancer Biomark.* 2013;13(5):395-401.

24466274 Shen W, Song M, Liu J, et al. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. *PLoS One.* 2014;9(1):e86871.

24481716 Chen Q, Ge X, Zhang Y, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. *Oncol Rep.* 2014;31(4):1863-1870.

24498016 McDermott AM, Miller N, Wall D, et al. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. *PLoS One.* 2014;9(1):e87032.

24513341 Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. *Gene.* 2013.

24523873 Zhu W, He J, Chen D, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. *PLoS One.* 2014;9(2):e87780.

24531034 Wu C, Cao Y, He Z, et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. *Tohoku J Exp Med.* 2014;232(2):85-95.

24578785 Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. *World J Gastrointest Oncol.* 2014;6(1):22-33.

24583788 Singh PK, Preus L, Hu Q, et al. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. *Oncotarget.* 2014;5(3):824-840.

24595006 Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. *Br J Cancer.* 2014.

24595450 Giray BG, Emekdas G, Tezcan S, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. *Mol Biol Rep.* 2014.

24600991 Zhu YJ, Xu B, Xia W. Hsa-mir-182 downregulates RASA1 and suppresses lung squamous cell carcinoma cell proliferation. *Clin Lab.* 2014;60(1):155-159.

24626859 Tsujiura M, Komatsu S, Ichikawa D, et al. Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. *Gastric Cancer.* 2014.

24646542 Frampton AE, Krell J, Gall TM, Castellano L, Stebbing J, Jiao LR. miR-15b and miR-17 Are Tumor-Derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia. *Ann Surg.* 2014.

24649179 Zhang GJ, Zhou T, Liu ZL, Tian HP, Xia SS. Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma. *Mol Clin Oncol.* 2013;1(2):379-384.

24651474 Wu C, Wang C, Guan X, et al. Diagnostic and Prognostic Implications of a Serum miRNA Panel in Oesophageal Squamous Cell Carcinoma. *PLoS One.* 2014;9(3):e92292.

24661838 Medina-Villaamil V, Martínez-Breijo S, Portela-Pereira P, et al. Circulating MicroRNAs in Blood of Patients With Prostate Cancer. *Actas Urol Esp.* 2014.

24664585 Yang Y, Qian J, Chen Y, Pan Y. Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis. *Tumour Biol.* 2014.